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ORIGINAL ARTICLES
A prospective 10 year follow up study of patients
with neurofibromatosis type 1
M H Cnossen, A de Goede-Bolder, K M van den Broek, C M E Waasdorp, A P Oranje,
H Stroink, H J Simonsz, A M W van den Ouweland, D J J Halley, M F Niermeijer
Abstract
Objective—To establish the prevalence
and incidence of symptoms and complica-
tions in children with neurofibromatosis
type 1 (NF1) and to assess possible risk
factors for the development of compli-
cations.
Design—A 10 year prospective multidisci-
plinary follow up study.
Patients—One hundred and fifty children
diagnosed with NF1 according to criteria
set by the National Institutes of Health.
Results—In 62 of 150 children (41.3%)
complications were present, including 42
(28.0%) children with one complication,
18 (12.0%) with two complications, and
two (1.3%) with three complications
(mean (SD) duration of follow up 4.9 (3.8)
years). Ninety five of the 150 children pre-
sented without complications (follow up,
340.8 person-years). The incidence of
complications was 2.4/100 person-years in
this group. An association was found
between behavioural problems and the
presence of complications.
Conclusion—This is the largest single
centre case series of NF1 aVected children
followed until 18 years of age. Children
with NF1, including those initially pre-
senting without complications, should
have regular clinical examinations.
(Arch Dis Child 1998;78:408–412)
Keywords: neurofibromatosis type 1; genetic disorders
Neurofibromatosis type 1 (NF1) is an auto-
somal dominant disorder aVecting one in every
3300 individuals. Half of all cases are sporadic
cases.1 Symptoms are highly variable and
severity cannot be predicted, even within fami-
lies. Diagnostic criteria for NF1 were estab-
lished by the National Institutes of Health con-
sensus development conference (NIH) in
1987.2
Characteristic features of the disease include
café au lait spots, axillary and inguinal
freckling, neurofibromas, and Lisch nodules.
Minor disease features seen in NF1 patients are
macrocephaly, short stature, hypertelorism,
thorax abnormalities, and learning, speech,
motor, and behavioural disorders. In child-
hood, various complications can occur such as
mental retardation, tumours of the central ner-
vous system (optic and chiasm gliomas),
orthopaedic abnormalities, endocrinological
disorders, and malignancies.3 4
Previously, only the prevalence of symptoms
and complications have been reported in NF1
patients. In this study, which includes the larg-
est reported series of children with NF1, we
determined both overall prevalence and inci-
dence rates of symptoms and complications in
150 children. Subsequently, we analysed possi-
ble risk factors for the development of compli-
cations.
Methods
PATIENTS AND FOLLOW UP
Since 1985, a multidisciplinary NF1 team in
the Sophia Children’s University Hospital in
Rotterdam including a paediatrician, derma-
tologist, paediatric neurologist, ophthalmolo-
gist, and clinical geneticist, has evaluated chil-
dren suspected of having NF1. At first visit,
clinical evaluations, x rays of the cranium and
the entire spine, and a visual evoked potential
were performed. In all NF1 aVected children,
irrespective of presence of complications,
follow up consisted of periodic clinical evalua-
tions supplemented by additional studies as
required. In this study, follow up was calculated
from first examination date with an NF1 diag-
nosis.
Computed tomography (CT) and magnetic
resonance imaging (MRI) of the brain were
only performed on indication—ophthalmologi-
cal abnormalities (optic atrophy, relative aVer-
ent pupillary defect, abnormal Ishihara colour
vision test, or abnormal visual evoked poten-
tial), endocrinological disorders, mental retar-
dation, and various other neurological abnor-
malities.
DEFINITIONS
Individual symptoms and complications were
defined as follows: mental retardation was
defined as attendance at a school for the men-
tally disabled; learning diYculties were defined
as attendance at a special school, other than a
school for the mentally disabled. Accordingly,
prevalence of mental retardation and learning
diYculties were established in children 6 years
and older (n = 110). Speech abnormalities
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were variable and often included late onset of
speech as well as articulatory problems. Coun-
selling by a speech therapist was recorded.
Motor problems were defined as clumsiness on
evaluation by a paediatric neurologist; support
by a physiotherapist was reported. Behavioural
problems varied from attention deficit hyperac-
tivity disorders to aggressive behaviour and
depression requiring psychiatric help.
Optic pathway gliomas reported in this study
were detected on CT/MRI scans of the brain.
Plexiform neurofibromas were defined as
either a large, soft swelling with ill defined
borders (diVuse plexiform neurofibroma) or a
firm, spherical or ovoid shaped swelling (nodu-
lar plexiform neurofibroma).4 Plexiform neuro-
fibromas were interpreted as complications on
the basis of either localisation or symptomatol-
ogy. Threatening localisations included the
head and neck, the vertebral column, para-
vertebrally and/or the perineum. Plexiform
neurofibromas causing severe symptoms (pain,
functional disorders, neurological deficits, and
cosmetic disfigurement) were also considered
to be complications.
Severe scoliosis was defined as a vertebral
column abnormality requiring treatment, such
as surgery or corset.
PREVALENCE RATES
Prevalence was calculated on the basis of a
symptom or complication on 1 January 1996 in
children (younger than 18 years of age)
diagnosed with NF1 according to NIH criteria.
Nine children examined before 1985 by all
specialists on a regular basis were also included
in this study. This population will be referred to
as group A (n = 150).
The prevalence of symptoms and complica-
tions at initial presentation can be calculated
easily by subtracting the number of occurring
symptoms/complications (n) from the overall
prevalence rate.
INCIDENCE RATES
Incidence rates of symptoms and complica-
tions were established on 1 January 1996 in
children (younger than 18 years of age) without
complications at presentation who were diag-
nosed with NF1. This group of children, which
is a subset of group A, will be called group B
(n = 95). These patients presented solely with
café au lait spots, freckling, Lisch nodules,
and/or dermal neurofibromas. Person-years,
the denominator of the incidence rate, was de-
fined by the first examination date with NF1
diagnosis and last examination date. Children
reaching the age of 18 years before January
1996 were considered withdrawn alive.
Incidence rates of newly presenting compli-
cations were also computed in children with
one or two complications at presentation. This
group will be referred to as group C (n = 55)
and is also a subset of group A. Person-years
were defined by first examination with NF1
diagnosis and complication(s) and last examin-
ation date. Complications were defined as new
when occurring more than one year after the
presenting complication(s).
ANALYSIS
Clinical data were obtained from medical
records and registered on a standardised form.
Data were analysed with Dbase IV and SPSS
6.0. Associations between specific symptoms
and the presence of complications were as-
sessed by univariate analysis with the ÷2 test
(p = 0.05, two sided). Risk factors tested
included sex; age at NIH diagnosis; physical
characteristics observed in children with NF1,
such as macrocephaly, short stature, hyperte-
lorism, thorax abnormalities, and mild scoli-
osis; as well as a variety of symptoms such as
learning diYculties, motor disorders, behav-
ioural problems and speech disorders.
Results
During this prospective follow up study, 209
children were examined for a suspected
diagnosis of NF1. NF1 was diagnosed accord-
ing to NIH criteria (table 1) in 150 children
(64 girls, 86 boys). Five children (3.3%) died of
malignancies during the follow up period.
Almost half of the NF1 aVected children
(46%) were referred by either a general practi-
tioner or other primary health care worker. The
others were referred by medical specialists.
PREVALENCE RATES
Prevalence rates of diagnostic criteria and
complications in group A are depicted in table
2. Mean (SD) age at last examination date was
10.4 (5.1) years. Mean (SD) duration of follow
up was 4.9 (3.8) years.
Diagnostic criteria
Six or more café au lait spots of the required
diameter were found in 96.7% of NF1 affected
children (mean age at presentation of sign, 3.1
(3.1) years). Freckling was found in 85.3%
(mean age at presentation of sign, 6.3 (4.2)
years). Dermal neurofibromas were found in
40.0% (mean age at presentation of sign, 8.9
(4.5) years). Plexiform neurofibromas were
found in 26.6%, Lisch nodules were found in
52.0% (mean age at presentation of sign, 8.8
(3.6) years), and a distinctive osseous lesion
(sphenoid dysplasia, thinning of long bone cor-
tex) was seen in 7.8% of NF1 affected children
(table 2). In addition, scalloping of the
vertebral bodies was seen in five (4.0%)
children and widened foramina of the vertebral
Table 1 NIH diagnostic criteria in neurofibramatosis type
1 (NF1). Two or more of the criteria are necessary for a
diagnosis of NF1
Clinical signs
Six or more café au lait spots over 5 mm in greatest diameter
in prepubertal individuals and over 15 mm in greatest
diameter in postpubertal individuals
Two or more neurofibromas of any type or one or more
plexiform neurofibroma
Freckling in the axillary or inguinal region
Optic or chiasma glioma
Two or more Lisch nodules (iris hamartomas)
A distinctive osseous lesion, such as sphenoid dysplasia or
thinning of long bone cortex, with or without bowing and
pseudoarthrosis
Family history
A first degree relative (parent, sibling, or oVspring) with NF1
by the above criteria
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bodies was seen in 10 (7.8%) children. In 74 of
150 (49.3%) cases one or more family
members were also diagnosed with NF1.
Minor disease features
Learning diYculties, speech abnormalities,
behavioural problems, and motor disorders
were seen in 33.0%, 58.7%, 47.3%, and 49.3%
of children, respectively. A speech therapist was
treating 76% of the children with speech
abnormalities. Support by a physiotherapist
was recorded in 66% of the children with
motor disorders. Data on macrocephaly, short
stature, hypertelorism, and thorax abnorma-
lities have been reported elsewhere.5
Complications
In summary, 62 group A patients (41.3%) had
one or more complication, including 42
(28.0%) children with one complication, 18
(12.0%) with two complications, and two
(1.3%) children with three complications. In
88 of 150 (58.7%) children no complications
had been diagnosed at last examination date.
Ophthalmological symptoms were seen in 10
of the 17 children with an optic pathway glioma
(58.8%). Three of the 17 (17.6%) children
with an optic pathway glioma received radio-
therapy owing to progressive visual loss. All but
one child with an optic pathway glioma had
abnormal visual evoked potentials at first pres-
entation. Children with an endocrinological
disorder after radiotherapy for an optic path-
way glioma were excluded from this analysis
(n = 2).
Three of four children with bowing of the
tibia developed pseudoarthrosis. One child
presented with bilateral bowing and unilateral
pseudoarthrosis, which is a rare condition.
Histology reports of malignant brain tumours
included two astrocytomas, one medulloblas-
toma, and one oligodendroglioma (grade III).
INCIDENCE RATES
Symptoms and complications
The total number of person-years in children
presenting without complications was 340.8.
The incidence of complications in group B is
depicted in table 3. In group B, 2.4 complica-
tions developed for each 100 person-years.
Complications developed in seven children
(one complication developed in six children
and two complications developed in one child).
Incidence rates were highest for optic pathway
glioma and plexiform neurofibroma. Univari-
ate analysis for possible risk factors in group B
showed an association between behavioural
problems and the presence of complications (÷2
test, p < 0.05).
Subsequent complications in children with
one or two complications at presentation are
depicted in table 4. The total number of
person-years in this subset was 322.6. In group
C, 3.0 complications developed for each 100
person-years. Most second/third complications
were endocrinological or a malignancy. One
patient with cervical dysplasias at presentation
experienced atlantoaxial dislocation after sur-
gery for a plexiform neurofibroma (Cnossen et
al, unpublished data). There was no significant
diVerence between the number of complica-
tions that developed in group B and group C
(95% confidence intervals (CI), −0.05, 0.07;
p > 0.05).
Discussion
This study presents prevalence and incidence
rates of symptoms and complications, recorded
during a prospective follow up study of a large
group of NF1 aVected children (n = 150).
Huson and colleagues7 documented the age
range of presentation and prevalence of major
complications in a smaller group of 39 NF1
patients who were younger than 18 years. Long
term prospective follow up of children with NF1
was determined necessary to define the natural
history of the disease. An analysis of the
prevalence and applicability of the diagnostic
criteria in children 6 years old and younger was
Table 2 Prevalence rates of diagnostic criteria, symptoms, and complications in 150
unselected neurofibromatosis type 1 (NF1) children (group A)
% (n)
Huson and
colleagues7¶ (%)
Obringer and
colleagues6 (%)
Diagnostic criteria
Café au lait spots 96.7 (145) 97–100 97.0
Freckling 85.3 (128) 70.0 81.0
Neurofibromas
Dermal 40.0 (60) 0–40 15.0
Plexiform* 26.6 (40) 25.7 −
Lisch nodules 52.0 (78) 79–85 30.0
Distinctive osseous lesion† 7.8 (11) − 6.0
Complications
Mental retardation 17.2 (19) 2.9 −
Optic pathway glioma 11.3 (17) 5.1 4.0
Epilepsy 0.7 (1) 5.1 –
Plexiform neurofibroma‡ 18.0 (27) 12.8 –
Bowing 2.7 (4) –
Pseudoarthrosis 2.0 (3) 7.8 6.0
Hemihypertrophy 2.7 (4) – –
Severe scoliosis 2.0 (3) 2.6 –
Aqueduct stenosis 0.7 (1) 2.1 –
Atlantoaxial dislocation 0.7 (1) – –
Endocrinological disorder 4.6 (7) – –
Central precocious puberty 2.0 (3) – –
Growth hormone deficiency 2.0 (3) – –
Diencephalic syndrome 0.7 (1) – –
Malignancy§ 4.0 (6) 1.5** 5.0
Neurofibrosarcoma 2.0 (3) – –
Malignant brain tumour 2.7 (4) – –
*Total number of plexiform neurofibromas; †sphenoid and occipital dysplasia (number of x rays/
computed tomography scans of skull = 138) and congenital bowing; ‡plexiform neurofibromas
considered as complications; §one child was diagnosed with both an astrocytoma and a neurofib-
rosarcoma; ¶If available, percentages shown in NF1 patients < 18 years (n = 39); **both
rhabdomyosarcomas.
Table 3 Incidence rates of complications in 95 children
presenting without complications (group B)
Incidence rates/
100 person-years (n)
Optic pathway glioma 1.2 (4)
Plexiform neurofibroma 0.6 (2)
Atlantoaxial dislocation 0.3 (1)
Endocrinological disorder 0.3 (1)
Table 4 Incidence rates of subsequent complications in 55
children presenting with one or two complications (group
C)
Incidence rate/
100 person-years (n)
Optic pathway glioma 0.3 (1)
Plexiform neurofibroma 0.3 (1)
Severe scoliosis 0.3 (1)
Atlantoaxial dislocation 0.3 (1)
Endocrinological disorder 0.9 (3)
Malignancy 0.9 (3)
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given by Obringer and colleagues.6 However,
descriptions of complications were not included.
PREVALENCE RATES OF SYMPTOMS AND
COMPLICATIONS
Strikingly, in the study population as a whole,
complications were observed in 42%; more-
over, one third of these children had two or
more complications of the disease.
The prevalence of the diagnostic criteria and
severe scoliosis were similar to those reported
in other studies.2 6 7
Prevalence rates of learning diYculties, motor
disorders, behavioural problems, and speech
disorders were similar to those reported in other
studies.8 9 The high percentages of these prob-
lems emphasises the necessity of following up
NF1 aVected children and informing their
parents about the association of these symptoms
with the disease, so that educational and
supportive measures can be taken.
The prevalence of optic pathway glioma has
been variously reported, depending on the
indication for brain imaging: 19%, if carried
out routinely10; 11.3%, if performed because of
suspected central nervous system tumours, eye
problems and/or endocrinological abnormali-
ties (this study); 5.1%, if carried out because of
suspected eye problems.7 We agree that routine
neuroimaging for optic pathway glioma is not
indicated because only half of the detected
optic pathway gliomas in our study were symp-
tomatic; one third of these presented with pro-
gressive visual loss. One of the three children in
this series had central precocious puberty and
an optic pathway glioma was found on MRI
examination. This is in contrast with earlier
observations of concurrence of chiasma glioma
in all NF1 patients with central precocious
puberty.11
Distinct from Huson and colleagues,7 none
of the NF1 patients in this series had a
rhabdomyosarcoma. Therefore, our data sug-
gest that this is a rare complication. Prevalence
of epilepsy, pseudoarthrosis, and aqueduct ste-
nosis were higher in the Welsh study. Contrast-
ingly, except for two patients with delayed
puberty, Huson did not observe any children
with endocrinological disorders.7
INCIDENCE RATES OF SYMPTOMS AND
COMPLICATIONS
In the group presenting without complications,
2.4 complications developed for each 100
person-years. By way of illustration, follow up
of 20 children presenting without complica-
tions for five years would lead to the discovery
of more than two complications in the total
group. This may not seem impressive but the
complications in NF1 are severe and cause
both serious morbidity and mortality. We feel
that follow up of children is indicated on the
basis of these data.
The incidence rate of subsequent complica-
tions in children presenting with one or two
complications was 3.0/100 person-years, not
significantly higher than in the group pres-
enting without complications.
Because this is the first study on incidence
rates of symptoms and complications in NF1
patients, there are no comparative data avail-
able. Although most of those with plexiform
neurofibromas (88.9%) and optic pathway
gliomas (70.6%) presented with symptoms at
initial examination, they might also develop
symptoms later on and present during follow
up. Accordingly, optic pathway gliomas have
been reported to develop in patients without
abnormalities on MRI scan at presentation.12
However, most endocrinological disorders
(57.1%) presented during follow up (table 4).
Therefore, deviations from the growth velocity
curve and premature manifestations of puberty
should be recognised as possible endocrine
complications of NF1. Malignancies were all
acquired during follow up. Half of the present-
ing tumours developed in pre-existing plexi-
form neurofibromas.
An association was found between behav-
ioural problems and the development of
complications. However, behavioural problems
may also be a consequence of complications in
children and as such cannot be considered a
risk factor.
FUTURE PROSPECTS AND RECOMMENDATIONS
Our data indicate that routine x rays of the cra-
nium and the entire spine are unnecessary,
unless symptoms indicate these investigations.
The observation of one case of atlantoaxial dis-
location in a patient with cervical dysplasias
and the 11.8% prevalence of this condition in
NF1 leads to our recommending complete
bidirectional cervical vertebral column x rays in
all NF1 patients undergoing anaesthesia and/or
surgery. Visual evoked potentials were a
valuable addition to the ophthalmological
examination at first presentation. Although the
specificity of this test is low, sensitivity is high,13
leading to detection and treatment of progress-
ive optic pathway glioma at an early stage.
Our data provide justification for follow up
of NF1 patients because they give the preva-
lence of complications at presentation, the
increase of complications (incidence rate), and
the overall prevalence of specific complica-
tions. We conclude that NF1 is a disease that is
associated with various psychomotor problems
and severe complications during childhood.
The children merit regular surveillance by an
experienced paediatrician, paediatric neurolo-
gist, and ophthalmologist. Factors predis-
posing children with NF1 towards the develop-
ment of complications remain to be
determined. Children without complications
should be seen every one to two years, unless
problems arise earlier. Children with complica-
tions at presentation should be examined more
frequently. These children do not have a higher
risk of subsequent complications than children
presenting without complications. We hope
that our prospective follow up study will be
useful for physicians and clinical geneticists
caring for NF1 patients and informing families
about the nature and progress of the disease.
Many thanks to our NF1 patients and their parents for their
cooperation. Special thanks to D FMajoor-Krakauer for initiat-
ing the neurofibromatosis project and to Dr H AMoll and Dr C
M van Duijn for their advice with regard to the protocol of the
study and for critical reading of the manuscript.
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